Julio Barraza-Vengoechea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Julio Barraza-Vengoechea has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Rodríguez-Alonso
Servicio de Medicina Interna, Unidad de Enfermedades Infecciosas, Hospital Universitario de Salamanca (HUS), Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca (USAL), Salamanca, Spain
1 shared publication - Carlos Dueñas
Hospital Clínico de Valladolid Valladolid Spain
1 shared publication - Carolina Iglesias-Echevarria
Cardiology Department Hospital Clínico Universitario Valladolid Spain saludcastillayleon.es
1 shared publication - Cristina Ybarra-Falcón
Cardiology Department Hospital Clínico Universitario Valladolid Spain saludcastillayleon.es
1 shared publication - David Andaluz-Ojeda
Department of Intensive Care Medicine, Complejo Asistencial Universitario de Palencia, 34005 Palencia, Spain
1 shared publication E. Ortega-Alonso
Hospital Universitario de Burgos, Burgos, España
1 shared publication
Latest Publications
- Open Access
- 1 March 2021
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 96 (3) , 115-116
Nuestra experiencia como oftalmólogos colaborando en la atención médica en pacientes COVID-19
- 1 March 2021
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 96 (3) , 115-116
Open AccessNuestra experiencia como oftalmólogos colaborando en la atención médica en pacientes COVID-19
- Open Access
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Corticosteroid Pulses for Hospitalized Patients with COVID‐19: Effects on Mortality
Objectives. To assess the influence of corticosteroid pulses on 60‐day mortality in hospitalized patients with severe COVID‐19. Methods. We designed a multicenter retrospective cohort study in three teaching hospitals of Castilla y León, Spain (865,096 people). We selected patients with confirmed COVID‐19 and lung involvement with a pO2/FiO2Results. From 2933 patients, 257 fulfilled the inclusion and exclusion criteria. 124 patients were on corticosteroid pulses (250 mg of methylprednisolone for three days), and 133 were not. 30.3% (37/122) of patients died in the corticosteroid pulse group and 42.9% (57/133) in the nonexposed cohort. These differences (12.6%, 95% CI [8·54‐16.65]) were statically significant (log‐rank 4.72, p = 0, 03). We performed PSM using the exact method. Mortality differences remained in the PSM group (log‐rank 5.31, p = 0.021) and were still significant after a Cox regression model (HR for corticosteroid pulses 0.561; p = 0.039). Conclusions. This study provides evidence about treatment with corticosteroid pulses in severe COVID‐19 that might significantly reduce mortality. Strict inclusion and exclusion criteria with that selection process set a reliable frame to compare mortality in both the exposed and nonexposed groups.
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Open AccessCorticosteroid Pulses for Hospitalized Patients with COVID‐19: Effects on Mortality
Objectives. To assess the influence of corticosteroid pulses on 60‐day mortality in hospitalized patients with severe COVID‐19. Methods. We designed a multicenter retrospective cohort study in three teaching hospitals of Castilla y León, Spain (865,096 people). We selected patients with confirmed COVID‐19 and lung involvement with a pO2/FiO2Results. From 2933 patients, 257 fulfilled the inclusion and exclusion criteria. 124 patients were on corticosteroid pulses (250 mg of methylprednisolone for three days), and 133 were not. 30.3% (37/122) of patients died in the corticosteroid pulse group and 42.9% (57/133) in the nonexposed cohort. These differences (12.6%, 95% CI [8·54‐16.65]) were statically significant (log‐rank 4.72, p = 0, 03). We performed PSM using the exact method. Mortality differences remained in the PSM group (log‐rank 5.31, p = 0.021) and were still significant after a Cox regression model (HR for corticosteroid pulses 0.561; p = 0.039). Conclusions. This study provides evidence about treatment with corticosteroid pulses in severe COVID‐19 that might significantly reduce mortality. Strict inclusion and exclusion criteria with that selection process set a reliable frame to compare mortality in both the exposed and nonexposed groups.